SCHEMBL3429330

SCHEMBL3429330

CCCS(=O)(=O)N1CCC1C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
KDM4E B2RXH2 4/20 0.43
LMNA P02545 2/20 0.40
FKBP1A P62942 2/20 0.40
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
GAA P10253 1/20 0.38
PKM P14618 1/20 0.38
MAPT P10636 1/20 0.38
ALOX15 P16050 1/20 0.37
KMT2A Q03164 1/20 0.37
MMP1 P03956 1/20 0.37
MMP7 P09237 1/20 0.37
MMP8 P22894 1/20 0.37
MMP12 P39900 1/20 0.37
MMP13 P45452 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3429323 1.00 ALDH1A1 (0.43) ALDH1A1KDM4ELMNAFKBP1ANPC1
SCHEMBL9103345 0.91 FKBP1A (0.47) ALDH1A1KDM4EFKBP1ACYP1A2KMT2A
SCHEMBL9103351 0.91 FKBP1A (0.47) ALDH1A1KDM4EFKBP1ACYP1A2KMT2A
SCHEMBL10815653 0.88 FKBP1A (0.48) ALDH1A1KDM4EFKBP1AMAPTMMP1
SCHEMBL26212073 0.81 FKBP1A (0.51) ALDH1A1FKBP1AMAPTMMP1MMP7
SCHEMBL3256301 0.80 FKBP1A (0.56) ALDH1A1FKBP1AMMP1MMP7MMP8
SCHEMBL3256303 0.80 FKBP1A (0.56) ALDH1A1FKBP1AMMP1MMP7MMP8
SCHEMBL6830973 0.79 FKBP1A (0.58) FKBP1AMMP1MMP7MMP8MMP12
SCHEMBL6830972 0.79 FKBP1A (0.58) FKBP1AMMP1MMP7MMP8MMP12
SCHEMBL7305308 0.78 POLB (0.48) ALDH1A1KDM4ELMNARAB9ACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443107-B1 AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2018-08-08 EP disclosed
US-8383615-B2 Azetidine 2-carboxamide derivatives which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-02-26 US disclosed
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-07 US disclosed
WO-2010147791-A1 AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 ALDH1A1 1724/4885KDM4E 1578/4885LMNA 4544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.